PTEN and prostate cancer: To date, oncomiRs such as miR-17, miR-20a, miR-21, miR-22, miR-25, miR-93, miR-106a/b, miR-153, miR-498 and miR-4534 have each demonstrated the ability to downregulate PTEN expression in prostate cancer cells, thus presenting potential therapeutic targets [112,113,114,115,116,117,118,119,120].